Cargando…
Once-yearly zoledronic acid in hip fracture prevention
Osteoporosis is an escalating global problem. Hip fractures, the most catastrophic complication of osteoporosis, continue to cause significant mortality and morbidity despite increasing availability of effective preventative agents. Among these agents, oral bisphosphonates have been the first choice...
Autores principales: | Demontiero, Oddom, Duque, Gustavo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685236/ https://www.ncbi.nlm.nih.gov/pubmed/19503777 |
Ejemplares similares
-
Differing approaches to falls and fracture prevention between Australia and Colombia
por: Gomez, Fernando, et al.
Publicado: (2013) -
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
por: Lambrinoudaki, Irene, et al.
Publicado: (2008) -
Implementation of an electronic care pathway for hip fracture patients: a pilot before and after study
por: Talevski, Jason, et al.
Publicado: (2020) -
The effects of dietary fatty acids on bone, hematopoietic marrow and marrow adipose tissue in a murine model of senile osteoporosis
por: Bani Hassan, Ebrahim, et al.
Publicado: (2019) -
Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
por: Carmona, Raj, et al.
Publicado: (2009)